On the stock market since 2021, it operates in the world of health and science. It has 14,846 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 6% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 71% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $5.2B in the vault; even if every debt were paid off, $2.7B would remain.
It pays out $0.02 per share each year — regular cash for whoever holds the stock.
A loss of $342.1M against $14.7B in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.16. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, CHIZF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CHIZF has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.